Author Affiliations: Institute of Public Health and Clinical Nutrition, University of Eastern Finland.
Since the original report by van Dam et al,1 coffee drinking has been associated with a decreased risk of type 2 diabetes mellitus in a number of epidemiological studies. However, body iron has for over a century been known to cause diabetes if in overt excess, manifested as the “bronzed diabetes”–hereditary hemochromatosis. We hypothesize in line with Mascitelli et al2 in their letter to the editor regarding a study by Pereira et al3 that the protective effect that coffee shows toward type 2 diabetes mellitus is perhaps, at least partially, explained by the iron absorption inhibitory effect of coffee. If this were so, subjects who consume much coffee should have both lower body iron stores and better glucose homeostasis compared with people who drink less or no coffee.
We looked at the association of coffee consumption with body iron and glucose homeostasis in 2682 men, aged 42 to 60 years, in the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD) in eastern Finland. The KIHD study has been approved by the joint research ethics committee of the University of Kuopio and Kuopio University Hospital. Dietary intake of foodstuffs was estimated by a 4-day food record,4 body iron was assessed as serum ferritin concentration, and glucose homeostasis was studied by the updated homeostasis model assessment (HOMA2) insulin resistance (IR) and pancreatic β-cell function (%β). The steady-state nonlinear HOMA2 models the interplay between hepatic glucose output, body glucose uptake, and insulin secretion and produces computational IR and %β parameters.5 The model sets the normal IR to 1.0 and the normal %β to 100. Ferritin, glucose, and insulin measurements were carried out in fasting state samples, as previously described.6
The mean (SD) values for the study subjects was 53.1 (5.1) years for age; 566 (297) mL/d for coffee intake; 168 (152) μg/L for serum ferritin concentration; 1.51 (0.89) for IR; and 112% (39%) for %β.
In an unadjusted linear regression model, IR decreased 2.1% per 100-mL increase in coffee intake and %β decreased 0.8%. Adjustment for ferritin level attenuated the association of coffee intake with IR from −0.021 (P < .001) to −0.009 (P = .03) (difference, −54%) and the association of coffee intake with %β from −0.843 (P = .001) to −0.706 (P = .008) (difference, −16%).
In the multivariate-adjusted linear regression models, serum ferritin adjustment weakened the age- and body mass index (BMI)-adjusted association of coffee intake with IR markedly (Table, model 2). Multivariate analyses of coffee intake and %β were very resistant to adjustments. Furthermore, serum ferritin concentration was not associated with %β in these models, probably because adding BMI to our statisical model made the association between iron and B-cell function disappear (regression coefficient, −0.002 [P = .96] with BMI [Table, model 2] vs 0.200 [P < .001] without BMI [model not shown]). Further adjustment for other dietary factors that relate to iron balance, such as intakes of red meats, vegetables, and milk, and for total energy intake did not confound the observed associations significantly (data not shown).
These results suggest that coffee consumption may be associated with both body iron stores and glucose homeostasis as measured by HOMA2 IR and HOMA2 %β. Furthermore, the results suggest that the association of coffee intake with IR may be partially explained by a decrease in body iron level.
Correspondence: Dr Tuomainen, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland (Tomi-Pekka.Tuomainen@uef.fi).
Author Contributions:Study concept and design: Tuomainen, Lagundoye, and Voutilainen. Acquisition of data: Tuomainen, Lagundoye, and Voutilainen. Analysis and interpretation of data: Tuomainen, Lagundoye, and Voutilainen. Drafting of the manuscript: Tuomainen, Lagundoye, and Voutilainen. Critical revision of the manuscript for important intellectual content: Tuomainen, Lagundoye, and Voutilainen. Statistical analysis: Tuomainen. Obtained funding: Tuomainen. Administrative, technical, and material support: Tuomainen. Study supervision: Tuomainen.
Financial Disclosure: None reported.
Funding/Support: This study was partially funded by a Juho Vainio Foundation grant to Dr Tuomainen.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.